Miltenyi Biomedicine Gmbh
Clinical trials sponsored by Miltenyi Biomedicine Gmbh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on tough blood cancers in early trial Results expected Sep 2026 (estimated)
- Personalized dosing may improve stem cell transplant survival in blood cancer patients Results expected Sep 2026 (estimated)
- Engineered immune cells take on tough lymphomas Results expected Dec 2026 (estimated)
- Engineered immune cells take on tough lymphoma in new trial Results expected Jan 2027 (estimated)
-
New CAR-T therapy aims to stop High-Risk lymphoma early
Disease control Not yet recruitingThis Phase 2 trial tests a CAR-T cell therapy called zamtocabtagene autoleucel as a first-line consolidation treatment for people with high-risk mantle cell lymphoma. About 52 participants will receive the therapy after standard chemotherapy. The main goal is to see how long they…
Phase 2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Personalized dosing may improve stem cell transplant survival in blood cancer patients
Knowledge-focused Not yet recruitingThis study compares survival and other outcomes in patients with acute leukemia or myelodysplastic syndrome who received a stem cell transplant with a personalized dose of an immune-suppressing drug (r-ATG) to similar patients from a large registry who received standard treatment…
Sponsor: Miltenyi Biomedicine GmbH • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC